<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Chloramphenicol: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Chloramphenicol: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Chloramphenicol: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="9241" href="/d/html/9241.html" rel="external">see "Chloramphenicol: Drug information"</a> and <a class="drug drug_patient" data-topicid="11324" href="/d/html/11324.html" rel="external">see "Chloramphenicol: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F5708673"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Blood dyscrasias: </span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Serious and fatal blood dyscrasias (aplastic anemia, hypoplastic anemia, thrombocytopenia, and granulocytopenia) are known to occur after the administration of chloramphenicol. In addition, there have been reports of aplastic anemia attributed to chloramphenicol which later terminated in leukemia. Blood dyscrasias have occurred after both short-term and prolonged therapy with this drug. Chloramphenicol must not be used when less potentially dangerous agents will be effective. It must not be used in the treatment of trivial infections or where it is not indicated, as in colds, influenza, infections of the throat; or as a prophylactic agent to prevent bacterial infections.</p>
<p style="text-indent:-2em;margin-left:2em;">It is essential that adequate blood studies be made during treatment with the drug. While blood studies may detect early peripheral blood changes, such as leukopenia, reticulocytopenia, or granulocytopenia, before they become irreversible, such studies cannot be relied on to detect bone marrow depression prior to development of aplastic anemia. To facilitate appropriate studies and observation during therapy, it is desirable that patients be hospitalized.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52866291"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Chloromycetin Succinate</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1046221"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antibiotic, Miscellaneous</span></li></ul></div>
<div class="block don drugH1Div" id="F53462403"><span class="drugH1">Dosing: Neonatal</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Follow serum concentrations closely to monitor for toxicity and efficacy in neonates due to variability in metabolism; use should be restricted to treatment of serious infections caused by susceptible organisms when less toxic drugs are ineffective (ie, resistance) or contraindicated.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ea65a8b1-e322-4417-b372-ae2b2b3d970d">Meningitis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Meningitis</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15494903']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15494903'])">Ref</a></span>): <b>Note:</b> Treat for a minimum of 21 days; use smaller doses and longer intervals for neonates &lt;2 kg:</p>
<p style="text-indent:-2em;margin-left:4em;">PNA ≤7 days: IV: 25 mg/kg/dose every 24 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">PNA 8 to 28 days: IV: 25 mg/kg/dose every 12 hours or 50 mg/kg/dose every 24 hours.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="63e6329d-0035-4c89-ba5f-d4a49395e5f1">Severe infections</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Severe infections:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Weight-based dosing:</i> Limited data available (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2179837']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2179837'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:6em;">&lt;1,200 g and ≤28 days: IV: 22 mg/kg/dose every 24 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">1,200 to 2,000 g and ≤7 days: IV: 25 mg/kg/dose every 24 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Age-based dosing: </i> Limited data available:</p>
<p style="text-indent:-2em;margin-left:6em;">Premature neonate or term neonate with PNA ≤7 days: Dosing regimens variable: IV: 25 mg/kg/dose every 24 hours or initiation with a loading dose of 20 mg/kg followed 12 hours later by a maintenance regimen of 12.5 mg/kg/dose every 12 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7143156','lexi-content-ref-6839629','lexi-content-ref-13843700']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7143156','lexi-content-ref-6839629','lexi-content-ref-13843700'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Term neonate with PNA &gt;7 days: Dosing regimens variable: IV: 25 mg/kg/dose every 12 hours or 12.5 mg/kg/dose every 6 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-6839629','lexi-content-ref-13843700']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-6839629','lexi-content-ref-13843700'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dop drugH1Div" id="F149462"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Follow serum concentrations closely to monitor for toxicity. Use should be restricted to treatment of serious infections when less toxic drugs are ineffective (ie, resistance) or contraindicated. Chloramphenicol palmitate (oral formulation) is no longer available in the US; chloramphenicol sodium succinate (IV formulation) continues to be available.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="fe17c72a-1c29-439a-80b0-593f970c6e4f">Meningitis and nonmeningeal pneumococcal infections</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Meningitis and nonmeningeal pneumococcal infections:</b> Limited data available: Infants, Children, and Adolescents: IV: 18.75 to 25 mg/kg/dose every 6 hours; maximum daily dose: 4,000 mg/<b>day</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15494903','lexi-content-ref-Kliegman.1','lexi-content-ref-AAP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15494903','lexi-content-ref-Kliegman.1','lexi-content-ref-AAP.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="63e6329d-0035-4c89-ba5f-d4a49395e5f1">Severe infections</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Severe infections:</b> Infants, Children, and Adolescents: IV: 12.5 to 25 mg/kg/dose every 6 hours; maximum daily dose: 4,000 mg/<b>day</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Kliegman.1','lexi-content-ref-AAP.1','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Kliegman.1','lexi-content-ref-AAP.1','lexi-content-ref-Manu.1'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51084653"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">All patients: There are no dosage adjustments provided in the manufacturer's labeling; use with caution, reduced dosage and serum concentration monitoring is recommended.</p></div>
<div class="block dohp drugH1Div" id="F51084654"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">All patients: There are no dosage adjustments provided in the manufacturer's labeling; use with caution, reduced dosage and serum concentration monitoring is recommended.</p></div>
<div class="block doa drugH1Div" id="F149440"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="9241" href="/d/html/9241.html" rel="external">see "Chloramphenicol: Drug information"</a>)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Usual dosage range:</b>
<b>IV:</b> 50 mg/kg/day in divided doses every 6 hours; an increased dosage up to 100 mg/kg/day may be required in some cases, but should be decreased as soon as possible (manufacturer's labeling). Maximum daily dose: 4 g/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34264565','lexi-content-ref-Moffa.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34264565','lexi-content-ref-Moffa.1'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="82c2b141-c61f-4f6a-9e90-3647d9c992d9">Plague, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Plague (<i>Yersinia pestis</i>), treatment:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Consult public health officials for event-specific recommendations. Dose based on total body weight, including in patients with obesity and those who are underweight (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34264565']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34264565'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Bubonic, pharyngeal, pneumonic, or septicemic plague (alternative agent)</i>: <b>IV:</b> 12.5 mg/kg (maximum: 1 g /dose) every 6 hours for 10 to 14 days and for at least a few days after clinical resolution (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34264565','lexi-content-ref-Stout.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34264565','lexi-content-ref-Stout.1'])">Ref</a></span>). For severe infections, a higher dose (25 mg/kg [maximum: 1 g/dose] every 6 hours) may be needed; reduce dose to 12.5 mg/kg (maximum: 1 g/dose) every 6 hours as soon as possible with clinical improvement (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34264565']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34264565'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Plague meningitis</i>: <b>Note:</b> For initial treatment of patients who present with meningitis symptoms, use as part of an appropriate combination regimen; add chloramphenicol to existing antimicrobial regimen in patients who develop secondary plague meningitis.</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>IV:</b> 25 mg/kg (maximum: 1 g/dose) every 6 hours; may reduce dose to 12.5 mg/kg (maximum: 1 g/dose) every 6 hours after clinical improvement. Recommended duration is 10 to 14 days and for at least a few days after clinical resolution when used for initial treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34264565','lexi-content-ref-Stout.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34264565','lexi-content-ref-Stout.1'])">Ref</a></span>); for secondary plague meningitis when chloramphenicol is added to existing therapy, continue entire regimen for an additional 10 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34264565']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34264565'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50992089"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no specific dosage adjustments provided in the manufacturer's labeling; however, dosage adjustment may be necessary. Use with caution; monitor serum concentrations.</p></div>
<div class="block doha drugH1Div" id="F50989304"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no specific dosage adjustments provided in the manufacturer's labeling; however, dosage adjustments may be necessary. Use with caution; monitor serum concentrations.</p></div>
<div class="block adr drugH1Div" id="F149402"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Acute generalized exanthematous pustulosis (Lee 1999), skin rash (Haile 1977)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Diarrhea (Haile 1977), glossitis (Haile 1977), nausea (Haile 1977), vomiting (Haile 1977)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Hemoglobinuria (paroxysmal nocturnal)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Aplastic anemia (Schmitt-Gräff 1981), bone marrow depression (Ferguson 1953), glucose-6-phosphate dehydrogenase deficiency anemia (Haile 1977), granulocytopenia (Poulton 1955), hypoplastic anemia (Todd 1954), immune thrombocytopenia (Poulton 1955), leukemia (Haile 1977), leukopenia (Haile 1977), neutropenia (Haile 1977), pancytopenia, sideroblastic anemia (Haile 1977), thrombocytopenia (Haile 1977)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity reaction (including angioedema) (Haile 1977)</p>
<p style="text-indent:-2em;margin-left:4em;">Immunologic: Jarisch-Herxheimer reaction (Haile 1977)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Confusion (Levine 1970), delirium (Levine 1970)<i>,</i> depression, encephalopathy (including asterixis, hallucination) (Levine 1970), headache</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Optic atrophy (Keith 1964), optic neuritis (Keith 1964)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Neonatal cyanosis (gray syndrome) (Mulhall 1983)</p></div>
<div class="block coi drugH1Div" id="F149418"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to chloramphenicol or any component of the formulation; treatment of trivial or viral infections; bacterial prophylaxis</p></div>
<div class="block war drugH1Div" id="F149399"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Gray syndrome: Characterized by cyanosis, abdominal distention, vasomotor collapse (often with irregular respiration), and death. Reaction appears to be associated with serum levels ≥50 mcg/mL (Powell 1982).</p>
<p style="text-indent:-2em;margin-left:4em;">• Superinfection: Prolonged use may result in fungal or bacterial superinfection, including <i>Clostridium difficile</i>–associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution; reduced dosage and serum concentration monitoring is recommended.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution; reduced dosage and serum concentration monitoring is recommended.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Glucose 6-phosphate dehydrogenase deficiency: Use with caution in patients with glucose 6-phosphate dehydrogenase deficiency.</p>
<p style="text-indent:-2em;margin-left:4em;">• Neonates: Use in premature and full-term neonates and infants has resulted in “gray syndrome" characterized by cyanosis, abdominal distention (with or without emesis), vasomotor collapse (often with irregular respiration), and death; progression of symptoms is rapid; prompt termination of therapy required. Reaction may result from drug accumulation caused by immature hepatic or renal function in neonates and infants.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Avoid prolonged or repeated courses of treatment.</p></div>
<div class="block foc drugH1Div" id="F149410"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 1 g (1 ea)</p></div>
<div class="block geq drugH1Div" id="F149395"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F16323057"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Chloramphenicol Sod Succinate Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 g (per each): $58.38</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52866292"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Chloromycetin Succinate: 1 g (1 ea)</p></div>
<div class="block adip drugH1Div" id="F53565749"><span class="drugH1">Additional Information</span>
<p style="text-indent:0em;display:inline">Sodium content of 1 g injection: 2.25 mEq.</p></div>
<div class="block admp drugH1Div" id="F52612399"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Parenteral:</p>
<p style="text-indent:-2em;margin-left:4em;">IV push: Administer over at least 1 minute.</p>
<p style="text-indent:-2em;margin-left:4em;">Intermittent IV infusion: Infuse over 30 to 60 minutes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10318297']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10318297'])">Ref</a></span>). In neonates, some centers have administered as an intermittent IV infusion over 15 minutes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2179837']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2179837'])">Ref</a></span>).</p></div>
<div class="block adm drugH1Div" id="F149415"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">IV: For IV use only; do not administer IM. Can be administered IVP over at least 1 minute at a concentration of 100 mg/mL.</p></div>
<div class="block hazard drugH1Div" id="F49130927"><span class="drugH1">Hazardous Drugs Handling Considerations</span>
<p style="text-indent:0em;">Hazardous agent (NIOSH 2016 [group 2]).</p>
<p style="text-indent:0em;margin-top:2em;">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage.</p>
<p style="text-indent:0em;margin-top:2em;">NIOSH recommends double gloving, a protective gown, ventilated engineering controls (a class II biological safety cabinet or a compounding aseptic containment isolator), and closed system transfer devices (CSTDs) for preparation. Double gloving, a gown, and (if dosage form allows) CSTDs are required during administration (NIOSH 2016). Assess risk to determine appropriate containment strategy (USP-NF 2017).</p></div>
<div class="block sts drugH1Div" id="F149428"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store intact vials at 20°C to 25°C (68°F to 77°F).</p></div>
<div class="block usep drugH1Div" id="F53565995"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">IV (chloramphenicol sodium succinate): Treatment of serious infections caused by susceptible organisms when less toxic drugs are ineffective or contraindicated (FDA approved in all ages).</p>
<p style="text-indent:0em;margin-top:2em;">
<b>Note: </b>Oral chloramphenicol palmitate is not available in the US.</p></div>
<div class="block mst drugH1Div" id="F149491"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Chloromycetin may be confused with chlorambucil, Chlor-Trimeton</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Pediatric patients: High-risk medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">KIDs List: Chloramphenicol, when used in neonates, is identified on the Key Potentially Inappropriate Drugs in Pediatrics (KIDs) list and should be avoided due to risk of gray baby syndrome unless serum concentration monitoring used (strong recommendation; high quality of evidence) (PPA [Meyers 2020]).</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F149480"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Inhibits</b> CYP2C9 (weak)</p></div>
<div class="block dri drugH1Div" id="F149404"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">5-Aminosalicylic Acid Derivatives: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alcohol (Ethyl): Chloramphenicol (Systemic) may enhance the adverse/toxic effect of Alcohol (Ethyl). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bacillus clausii: Antibiotics may diminish the therapeutic effect of Bacillus clausii.  Management: Bacillus clausii should be taken in between antibiotic doses during concomitant therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Carbocisteine: Chloramphenicol (Systemic) may enhance the adverse/toxic effect of Carbocisteine. Specifically, chloramphenicol may enhance adverse effects of alcohol that is present in liquid formulations of carbocisteine-containing products. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CefTAZidime: Chloramphenicol (Systemic) may diminish the therapeutic effect of CefTAZidime.  Management: Consider using a different combination of antimicrobials, especially if bactericidal activity is desired. If these agents are combined, monitor for reduced antimicrobial effectiveness and/or therapeutic failure.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine.  Management: Avoid cholera vaccine in patients receiving systemic antibiotics, and within 14 days following the use of oral or parenteral antibiotics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CycloSPORINE (Systemic): Chloramphenicol (Systemic) may increase the serum concentration of CycloSPORINE (Systemic).  Management: Cyclosporine dose reductions will likely be required with initiation of concurrent chloramphenicol.  Monitor cyclosporine concentrations and response closely following initiation and/or discontinuation of chloramphenicol.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone.  Management: Avoid the concomitant use of deferiprone and myelosuppressive agents whenever possible. If this combination cannot be avoided, monitor the absolute neutrophil count more closely.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fecal Microbiota (Live) (Oral): May diminish the therapeutic effect of Antibiotics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fecal Microbiota (Live) (Rectal): Antibiotics may diminish the therapeutic effect of Fecal Microbiota (Live) (Rectal). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: Myelosuppressive Agents may enhance the myelosuppressive effect of Fexinidazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fosphenytoin: May decrease the serum concentration of Chloramphenicol (Systemic). Fosphenytoin may increase the serum concentration of Chloramphenicol (Systemic). Chloramphenicol (Systemic) may increase the serum concentration of Fosphenytoin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies): Antibiotics may diminish the therapeutic effect of Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Myelosuppressive Agents: May enhance the myelosuppressive effect of Chloramphenicol (Systemic).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">PHENobarbital: May decrease the serum concentration of Chloramphenicol (Systemic). Chloramphenicol (Systemic) may increase the serum concentration of PHENobarbital.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Phenytoin: May decrease the serum concentration of Chloramphenicol (Systemic). Phenytoin may increase the serum concentration of Chloramphenicol (Systemic). Chloramphenicol (Systemic) may increase the serum concentration of Phenytoin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Primidone: Chloramphenicol (Systemic) may increase serum concentrations of the active metabolite(s) of Primidone. Specifically, the concentrations of phenobarbital may be increased. Primidone may decrease the serum concentration of Chloramphenicol (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Promazine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">RifAMPin: May increase the metabolism of Chloramphenicol (Systemic).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sulfonylureas: Chloramphenicol (Systemic) may increase the serum concentration of Sulfonylureas. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Systemic): Chloramphenicol (Systemic) may increase the serum concentration of Tacrolimus (Systemic).  Management: Reduce the tacrolimus dose and monitor tacrolimus whole blood concentrations frequently, beginning within 1 to 3 days of chloramphenicol initiation. Further tacrolimus dose adjustments should be guided by continued monitoring of tacrolimus levels.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Avoid use of live attenuated typhoid vaccine (Ty21a)  in patients being treated with systemic antibacterial agents. Postpone vaccination until 3 days after cessation of antibiotics and avoid starting antibiotics within 3 days of last vaccine dose.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin B12: Chloramphenicol (Systemic) may diminish the therapeutic effect of Vitamin B12. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin K Antagonists (eg, warfarin): CYP2C9 Inhibitors (Weak) may increase the serum concentration of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p></div>
<div class="block dic drugH1Div" id="F149422"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">May have increased dietary need for riboflavin, pyridoxine, and vitamin B<sub>12</sub>. Some products may contain sodium.</p></div>
<div class="block pri drugH1Div" id="F149420"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Chloramphenicol crosses the placenta producing cord concentrations approaching maternal serum concentrations. An increased risk of teratogenic effects has not been associated with the use of chloramphenicol in pregnancy (Czeizel 2000; Heinonen 1977). "Gray Syndrome" has occurred in premature infants and newborns receiving chloramphenicol.</p>
<p style="text-indent:0em;margin-top:2em;">Chloramphenicol may be used as an alternative agent for the treatment of Rocky Mountain spotted fever in pregnant patients although caution should be used when administration occurs during the third trimester (CDC [Biggs 2016]).</p>
<p style="text-indent:0em;margin-top:2em;">Untreated plague (<i>Yersinia pestis</i>) infections in pregnant patients may result in hemorrhage (including postpartum hemorrhage), maternal and fetal death, preterm birth, and stillbirth. Limited data suggest maternal-fetal transmission of <i>Y. pestis</i> can occur if not treated. Pregnant patients should be treated for <i>Y. pestis; </i>parenteral antibiotics are preferred for initial treatment when otherwise appropriate. Chloramphenicol may be used as an alternative antibiotic for treating pregnant patients with bubonic, pharyngeal, pneumonic, or septicemic plague (doses at the lower end of the adult dosing range should be sufficient for most patients). Recommendations for treating pregnant patients with plague meningitis are the same as in nonpregnant patients. Chloramphenicol can be added to the antibiotic regimen for treatment of secondary plague meningitis (CDC [Nelson 2021]).</p></div>
<div class="block mopp drugH1Div" id="F53565976"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">CBC with differential and platelet counts (baseline and every 2 days during therapy), serum iron level, iron-binding capacity, periodic liver and renal function tests, serum drug concentration.</p></div>
<div class="block rerp drugH1Div" id="F53565750"><span class="drugH1">Reference Range</span>
<p style="text-indent:-2em;margin-left:2em;">Therapeutic concentrations:</p>
<p style="text-indent:-2em;margin-left:4em;">Pediatric:</p>
<p style="text-indent:-2em;margin-left:6em;">Peak: Neonates: 15 to 25 mcg/mL (SI: 46.3 to 77.3 mcmol/L) (Muhall 1983); Infants, Children, and Adolescents: 15 to 30 mcg/mL (SI: 46.3 to 92.7 mcmol/L) (Balbi 2004; Coakley 1992; Long 2018).</p>
<p style="text-indent:-2em;margin-left:6em;">Trough: 5 to 15 mcg/mL (SI: 15.5 to 46.3 mcmol/L).</p>
<p style="text-indent:-2em;margin-left:4em;">Adult:</p>
<p style="text-indent:-2em;margin-left:6em;">Peak: 10 to 20 mcg/mL (SI: 30.9 to 61.8 mcmol/L) (Ambrose 1984; Hammet-Stabler 1998).</p>
<p style="text-indent:-2em;margin-left:6em;">Trough: 5 to 10 mcg/mL (SI: 15.5 to 30.9 mcmol/L) (Ambrose 1984).</p>
<p style="text-indent:-2em;margin-left:2em;">Timing of serum samples: Draw peak concentrations 0.5 to 1.5 hours after completion of IV dose; and trough immediately before next dose (Hammet-Stabler 1998).</p></div>
<div class="block pha drugH1Div" id="F149398"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Reversibly binds to 50S ribosomal subunits of susceptible organisms preventing amino acids from being transferred to growing peptide chains thus inhibiting protein synthesis</p></div>
<div class="block phk drugH1Div" id="F149417"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Distribution: To most tissues and body fluids (Ambrose 1984); good CSF and brain penetration</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">CSF concentration with uninflamed meninges: 21% to 50% of plasma concentration </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">CSF concentration with inflamed meninges: 45% to 89% of plasma concentration </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Chloramphenicol: V<sub>d</sub>: 0.6 to 1 L/kg (Ambrose 1984)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Chloramphenicol succinate: V<sub>d</sub>: 0.2 to 3.1 L/kg (Ambrose 1984)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Protein binding: Chloramphenicol: ~60%; decreased with hepatic or renal dysfunction and 30% to 40% in newborn infants (Ambrose 1984)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Metabolism: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Chloramphenicol: Hepatic to metabolites (inactive) (Ambrose 1984)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Chloramphenicol succinate: Hydrolyzed in the liver, kidney, and lungs to chloramphenicol (active) (Ambrose 1984)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Bioavailability:</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Chloramphenicol: Oral: ~80% (Ambrose 1984)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Chloramphenicol succinate: IV: ~70%; highly variable, dependent upon rate and extent of metabolism to chloramphenicol (Ambrose 1984)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Half-life elimination:</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Neonates: 1 to 2 days: 24 hours; 10 to 16 days: 10 hours</p>
<p style="text-indent:-2em;margin-left:6em;text-align:justify;">Chloramphenicol: Infants: Significantly prolonged (Powell 1982); Children 4 to 6 hours; Adults: ~4 hours (Ambrose 1984)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Hepatic disease: Prolonged (Ambrose 1984)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Excretion: Urine (~30% as unchanged chloramphenicol succinate in adults, 6% to 80% in children; 5% to 15% as chloramphenicol) (Ambrose 1984; Powell 1982)</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F2869368"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Apicol | Chloramex | Chlorampenicol | Chloromycetin | Chloroptic | Econochlor | Isopto fenicol | Kemicetine | Optichlor | Riachol | Spersanicol | Synthomycetine</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Chloromycetin | Farmicetina | Klonalfenicol | Poenfenicol | Quemicetina</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Chloramphenicol agepha | Halomycetin | Kemicetin | Oleomycetin</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Apo chloramphenicol | Chloromycetin | Chlorsig | Cholfen | Ocuzo | Terry White Chemists Chloramphenicol</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">A-Phenicol | Aristophen | Chemophenicol | Chloramex | Chloraphenicol | Chlorphen | Cloram | E col | Edrumycetin | Eyephen | Fionicol | Icol | Ocubac | Ocuclor | Ocuram | Ocutrex | Opsomycetin | Opsophenicol | Optabac | Optaphenicol | Opthacol | Optichlor | Otophenicol | Ramex | Ramicol | Ramphen | Reomphenicol | Spersanicol | Sq Mycetin | Stanophenicol | Staphenicol | Supraphen</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Chloramphenicol erfa | Chloramphenicol thea pharma | Chloramphenicol viatris | Fenicol</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Chlornitromycin</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Amplobiotic | Clorafenil | Cloramed | Cloranfenicol | Cloranfenil | Clorex | Clorfenil | Feniclor | Fenicloran | Neo fenicol | Profenicol | Quemicetina | Sintomicetina | Visalmin</span>;</li>
<li>
<span class="countryCode">(CI)</span> <span class="country">Côte d'Ivoire</span><span class="countrySeparator">: </span><span class="drugName">Oftalmolosa cusi chloramphenicol</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Chloromycetin | Cloranfenicol | Cloroptic | Gemitin | Kaph | Quemicetina | Spersanicol</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Ai ming | Chloramphenicol | Fu jie shu | Run shu</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Chloromycetin | Clorafenicol | Cloranfenicol | Miroptic | Quemicetina | Spersanicol</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Aquamycetin | Chloramsaar n | Paraxin | Posifenicol | Thilocanfol c</span>;</li>
<li>
<span class="countryCode">(DK)</span> <span class="country">Denmark</span><span class="countrySeparator">: </span><span class="drugName">Kloramfenikol viskoes dak</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Chloromycetin | Cloramfeni ofteno | Cloramfeni ungena | Cloramfenicol | Cloramicol | Cloramil | Cloranfenicol | Crisvin | Oftaclor | Optichlor | Sificetina</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Acromaxfenicol | Alfa cloromicol | Chloromycetin | Cloranfenicol | Cloroptic | Fenicol | Micoclorina | Spersanicol</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Laevomycetin | Oftan Akvakol | Sificetina | Synthomycin</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Adcocetine | Chloromycetin | Cidocetine | Epiphenicol | Isomiphenicol | Isoptofenicol | Levocol | Memcocetin | Memcocetine | Miphenicol | Ocuphenicol | Ophtamycetine | Ophtomycetine | Optocetine | Otophenicol</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Chloromycetin | Colircusi Cloramfenicol | Normofenicol | Oftalmolosa Cusi Cloramfenicol</span>;</li>
<li>
<span class="countryCode">(ET)</span> <span class="country">Ethiopia</span><span class="countrySeparator">: </span><span class="drugName">Abchlor | Clorocil | Kloraxin</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Chloramphenicol orifarm | Chloromycetin | Klorita | Oculo klorita | Oftan Akvakol | Oftan Chlora | Oftan-kloramfenikol | Otichlora</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Cebenicol</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Antibiotic Eye | Boots infected eyes | Brochlor | Chloramphen | Chloramphenic | Chloramphenic cox | Chloramphenicol almus | Chloramphenicol kent | Chloramphenicol sussex pharm | Chloromycetin | Chloromycetin p.d | Clorogen | Eykappo | Golden eye antibiotic | Kemicetine | Klorafect | Mollifeye | Ocumont | Optrex Bacterial Conjunctivitis | Optrex Infected Eye | Optrex infected eyes | Sno phenicol | Tubilux</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Chloranic | Kemicetine | Ursa fenol</span>;</li>
<li>
<span class="countryCode">(GT)</span> <span class="country">Guatemala</span><span class="countrySeparator">: </span><span class="drugName">Alfer nicol</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Aristophen | Chloment | Chloratets | Chloroph | Chlorsig | Elisca | Enicol | Europhen | Europhenicol | Isopto fenicol | Kemicetine | Lycofenicol | Lycophen | Neo phenicol | Opsaram | Optichlor | Optivis | Optomycin | Penicol | Phenicol | Silmycetin | Spersanicol | Vanafen | Venicol | Vyview top | Xepanicol</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Aromycetine | Bufacetin | Camicetine | Cendo fenicol | Cendo mycetine | Cendo mycine | Centraphenicol | Chloramet | Chloramex | Chloramidina | Chlorbiotic | Chloromycetin | Cloramidina | Colain | Colcetin | Colme | Colsancetine | Combicetin | Coromecytin | Decacetine | Denicol | Empeecetin | Enkacetyn | Erlamycetine | Farsycol | Fenicol | Grafacetin | Hufamycetin | Ikamicetin | Isotic salmicol | Itramycetine | Kalmicetin | Kalmicetine | Kemicetine | Kemocol | Kloramfenikol | Lanacetine | Librocetine | Magna Chloramphenicol | Mecocetin | Medichlor | Megachlor | Microtina | Neophenicol | Palmicol | Paraphenicol | Paraxin | Pharocetine | Reco | Recomycetin | Ribocine | Sakamycetin | Sinamycetin | Solachlor | Spersanicol | Suprachlor | Synthomycetine | Uniphenicol | Varicetine | Xepanicol</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Chloromycetin</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Chlorphenicol | Phenicol | Synthomycine | Tarophenicol</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Acronicol | Amphen | Andrecin | Biochlor | Biophenecol | Cadimycetin | Chloraxin | Chlormet | Chlorocin | Chlorocol | Chloromycetin | Chlorosun | Chlorotin | Daclor | Dexoren | Enteromycetin | Fencol | I-chlor | Kemicetine | Kemicetine otologi | Klorum | Larmycetin | Loram | Lykacetin | Microcetin | O-mycin | Ocuchlor | Optichlor | Opticol | Otochlor | Paraxin | Phenicach | Ranphenicol | Ranquel | Reclor | Renicol | Starphenicol | Tycol | Vanmycetin | Vecol | Venez | Vitchol | Wocol</span>;</li>
<li>
<span class="countryCode">(IQ)</span> <span class="country">Iraq</span><span class="countrySeparator">: </span><span class="drugName">Hayaphenicol | Samaphenicol</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Chemicetina | Chloromycetin | Cloramfen | Flogocyn | Ismicetina | Mycetin | Sificetina</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Chloroptic | Isopto fenicol | Kemicetine | Phenicol | Snophenicol</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Chloramphe.maruko | Chloramphe.t nitto | Chloramphenicol t galen | Chloromycetin | Kemicetine | Paraxin | Sankyo | Synthomycetine</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Axacrome | Biophenicol | Clomex | Cphen | Dawaphenicol | Elycetin | Eurocol | Ivychlornicol | Ivyphenicol | Mediphenicol | Metamycin | Ocumycin | Oramnicol | Rogophen | Salvaclor | Sq Mycetin | Xepanicol</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Chlorampenicol | Chloramphenicol unimed | Helocetin | Nicol | Ocuchloram | Opticle | Penicol | Spersanicol | Synthomycetine</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Chloramphenicol Chibret | Chloroptic | Isopto fenicol | Oftalmolosa cusi chloramphenicol | Optichlor | Spersanicol</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Novamycetin | Paramycetin | Spersanicol</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Chlornitromycin | Isopto fenicol | Laevosin | Levomycetin | Synthomycin</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Chloramphenicol erfa</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Chlornitromycin | Isopto fenicol | Laevomycetinum | Laevosin | Levomycetin | Oftan Akvakol | Synthomycin</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Cebenicol | Kemicetine</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Abefen | Amfenil | Amsamicetin | Chloromycetin | Cloramfeni ofteno | Cloramfeni ungena | Cloramfenic genetica | Cloramfenicol | Cloramfenicol gi | Cloramfenicol gi s | Cloramfenicol landsteiner | Cloramfenicol Ultra | Cloramfenil | Clorampler | Cloran | Cloran-micron | Cloranfenicol | Cloranfenicol alpharma | Cloranfenicol Bruluagsa | Cloranfenicol mavi | Cloratenol | Clorfenil | Exacol | Fenicol oftalmico | Fenizzard | Infebye | Lebrocetin | Omycet | Palmiclor | Paraxin | Quemicetina | Solfranicol | Solvaris | Spersanicol | Westenicol</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Beaphenicol | Chloram | Chlorop | Enclor | Eucomycin | Kloraxin | Nicol | Shinacol | Spersanicol | Xepanicol</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Cafcol | Cedanicol | Chlorakris | Derm chloramphenicol | Hanbet chloramphenicol | Lorasin | Mediphenicol | Nuel chloramphenicol | Optomycin | Pecaf | Varmycin</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Chlooramfenic | Chlooramfenicol HPS | Chlooramfenicol ratiopharm | Chlooramfenicol thea | Chlooramfenicol-pos | Chloramphenic | Globenicol</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Kloramfenikol | Kloramfenikol aurora medical | Kloramfenikol naf | Kloramfenikol santen</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Arrow chlorafast | Chlorafast | Chloromycetin | Chlorsig</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Chloromycetin | Cloramfenicol | Cloranfenicol | Clorin | Clorocid | Cloromisan | Cloroptic | Fenicol | Fenolyd | Queen cetina forte | Quemicetina | Sificetina | Spersanicol | Tifobiotic | Uniclor</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Alphagram otic | Anpheclor | Benchlor | Bioclor | Biogenerics chloramphenicol | Biomycetin | Boie chloramphenicol | C-Phenicol | Celsus Chloramphenicol | Chloramed | Chloramin | Chloramol | Chlorampheni | Chloramphenicol Ad-drugstel pharm | Chloramphenicol Allied | Chloramphenicol Flamingo | Chloramphenicol Parl lab | Chloro s | Chloro V | Chlorolem | Chloromycetin | Chrisochlor | Clorstel | Compacol | Dli-chloramphenicol | Drexclo | Fen-alcon | Forastrol | Genphenil | Gerafen | Harvox | Intermycetin | Kemicetine | Knolcol | Lafayette chloramphenicol | Lorpican | Medichlor | Medimycetin | Medoptic | Metacol | Metrophenicol | Micromycetin | Neocol | Neophenicol c | Oliphenicol | Pediachlor | Penachlor | Perastan | Pharex chloramphenicol | Plivacol | Rielcetin | Ritemed Chloramphenicol | Roddenmycin | Samonef | Scanicol | Sensomed chloramphenicol | Siloram | Spersanicol | Sustachlor | Sydencetin | Ul chloramphenicol | Vamcetin | Vanchlor | Venimicetin | Zerruchlor</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Alklorafen | Bentaphen | Biomycin | Chlorin | Chlormax | Chloromycetin | Chloroptic | Cloramidina | Comycetin | Econochlor | Fenicol | Fenoptic | Geoclor | Invoclor | Medichlor | Medichlor plus | Neophenicol | Novophenicol | O-mycetin | Opchlor | Ophth chlor | Optachlor | Orbachlor | Remicol | Rexaphenicol | Santochlor | Schazomycetin | Sificetina | Spersanicol | Vasochlor | Vechlor | Vitachlor</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Brochlor | Detreomycina | O.c.chloramphenico</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Antibiotic | Chloromycetin | Chloroptic</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Cloranfenicol | Clorocil | Dermimade cloranfenicol | Fenoptic | Kemicetine | Kemicetine oftalmo | Micetinoftalmina</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Cloranfenicol | Cloranfenicol dutriec | Cloranfenicol nicolich | Isopto fenicol | Lascamicetina | Novofenicol | Ofenicol | Spersanicol</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Cloramfenicol | Otophenicol</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Laevosin | Levomycetin | Levomycetin akos | Levomycetin ferein | Synthomycin</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Chloromycetin | Chloroptic | Econochlor | Fenicol | Isopto fenicol | Optichlor | Phenicol | Riachol | Spersanicol</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Chloromycetin | Isopto fenicol | Kloramfenikol ccs | Kloramfenikol santen</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Beaphenicol | Enclor | Isopto fenicol | Minims chloramphenicol | Optomycin | Spersanicol | Xepanicol</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Chloramphenicol agepha | Otomycin</span>;</li>
<li>
<span class="countryCode">(SL)</span> <span class="country">Sierra Leone</span><span class="countrySeparator">: </span><span class="drugName">Chloron</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Ambricol | Antibi-otic ear drops | Archifen | Bemomycetin | Bemomycin | Chloment | Chlor-pyrad | Chloracil | Chloramdon | Chloramno | Chloramo | Chloramphenicol | Chloroph | Chloroptic | Cogetine | Comycin | Coracetin | Fenicol | Genercin | Koro | Levomycetin | Lichlorcin | Manocetin | Mycochlorin | Nicolmycetin | Opsaram | Optivis | Paraxin | Pharmacetin | Phen | Phenicol | Pisalin | Primacetin | Ramacol | Silmycetin | Skarnchlor | Unison | Uto chloramphenicol | Vanafen | Vanafen-s</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Armisetin | Cebenicol | Devamycetin | Kemicetine</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Biomycin | C c mycin | C P | Chloment | Chloramphenical | Chlorlymin | Chlormycetin | Chlormycin | Chloromycetin | Hinicol | Inchlomycin | Isopto fenicol | Kemicetine | Keromycin | Kerromycin | Lomycin | Ocumicetin | Showen</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Chlorsig | Laevomycetin | Levomicin | Levomycetin | Synthomycin</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Abchlor | Agophenol | Ascaf | Aurocol | Fomycetin | Ivychlornicol | Ivyphenocol | Kam chlor | Ocumycin | Renechlor</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Beyonas clor | Cloramfenicol | Fenicol | Isopto fenicol | Spersanicol</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Chloromycetin | Cloftal | Cloramfenicol | Cloranfenicol</span>;</li>
<li>
<span class="countryCode">(VN)</span> <span class="country">Viet Nam</span><span class="countrySeparator">: </span><span class="drugName">Agichloram | Clorocid tw3</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Chloramex | Chlorcol | Chlornicol | Chloromycetin | Chlorphen | Kloraxin | Micro-chloramphenicol | Rolab-chloramphenicol | Spersanicol</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Allphenicol | Amphen | Chlornicol | Chlorphen | Dexoren | Dicimycin | Fomycetin | Ivychlornicol | Ivyphenicol | Kloraxin | Metamycin | Opticol | Paracetin</span>;</li>
<li>
<span class="countryCode">(ZW)</span> <span class="country">Zimbabwe</span><span class="countrySeparator">: </span><span class="drugName">Chlornicol</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-USP.1">
<a name="USP.1"></a>&lt;800&gt; Hazardous Drugs—Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary </i>(USP 40-NF 35). Rockville, MD: United States Pharmacopeia Convention; 2017:83-102.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6375931">
<a name="6375931"></a>Ambrose PJ. Clinical pharmacokinetics of chloramphenicol and chloramphenicol succinate. <i>Clin Pharmacokinet</i>. 1984;9(3):222-238.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chloramphenicol-pediatric-drug-information/abstract-text/6375931/pubmed" id="6375931" target="_blank">6375931</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-AAP.1">
<a name="AAP.1"></a>American Academy of Pediatrics (AAP). In: Kimberlin DW, Brady MT, Jackson MA, Long SA, eds. <i>Red Book: 2018 Report of the Committee on Infectious Diseases</i>. 31st ed. Itasca, IL: American Academy of Pediatrics; 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Aronoff.1">
<a name="Aronoff.1"></a>Aronoff GR, Bennett WM, Berns JS, et al, <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>, 5th ed. Philadelphia, PA: American College of Physicians; 2007.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3292101">
<a name="3292101"></a>Atkinson HC, Begg EJ, Darlow BA. Drugs in human milk. Clinical pharmacokinetic considerations. <i>Clin Pharmacokinet</i>. 1988;14(4):217-240.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chloramphenicol-pediatric-drug-information/abstract-text/3292101/pubmed" id="3292101" target="_blank">3292101</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15286274">
<a name="15286274"></a>Balbi HJ. Chloramphenicol: a review. <i>Pediatr Rev</i>. 2004;25(8):284-288.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chloramphenicol-pediatric-drug-information/abstract-text/15286274/pubmed" id="15286274" target="_blank">15286274</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27172113">
<a name="27172113"></a>Biggs HM, Behravesh CB, Bradley KK, et al. Diagnosis and management of tickborne rickettsial diseases: Rocky Mountain Spotted Fever and Other Spotted Fever Group Rickettsioses, Ehrlichioses, and Anaplasmosis - United States. <i>MMWR Recomm Rep</i>. 2016;65(2):1-44.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chloramphenicol-pediatric-drug-information/abstract-text/27172113/pubmed" id="27172113" target="_blank">27172113</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Bradley.1">
<a name="Bradley.1"></a>Bradley JS, Nelson JD, Kimberlin DK, et al, eds. <i>Nelson's Pocket Book of Pediatric Antimicrobial Therapy</i>. 19th ed. Philadelphia, PA: Lippincott Williams &amp; Wilkins; 2012.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16572105">
<a name="16572105"></a>Center for Disease Control and Prevention (CDC). Diagnosis and management of tickborne rickettsial diseases: Rocky Mountain spotted fever, ehrlichioses, and anaplasmosis - United States: a practical guide for physicians and other health-care and public health professionals. <i>MMWR Recomm Rep</i>. 2006. 55(RR-4):1-29.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chloramphenicol-pediatric-drug-information/abstract-text/16572105/pubmed" id="16572105" target="_blank">16572105</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Chloramphenicol Sodium Succinate [prescribing information]. Lake Zurich, IL: Fresenius Kabi USA; October 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1605978">
<a name="1605978"></a>Coakley JC, Hudson I, Shann F, Connelly JF. A review of therapeutic monitoring of chloramphenicol in patients with Haemophilus influenzae meningitis. <i>J Paediatr Child Health</i>. 1992;28(3):249-253.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chloramphenicol-pediatric-drug-information/abstract-text/1605978/pubmed" id="1605978" target="_blank">1605978</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6047242">
<a name="6047242"></a>Cocke JG Jr, “Chloramphenicol Optic Neuritis. Apparent Protective Effects of Very High Daily Doses of Pyridoxine and Cyanocobalamin,” <i>Am J Dis Child</i>, 1967, 114(4):424-6.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chloramphenicol-pediatric-drug-information/abstract-text/6047242/pubmed" id="6047242" target="_blank">6047242</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10959939">
<a name="10959939"></a>Czeizel AE, Rockenbauer M, Sørensen HT, Olsen J. A population-based case-control teratologic study of oral chloramphenicol treatment during pregnancy. <i>Eur J Epidemiol</i>. 2000;16(4):323-327.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chloramphenicol-pediatric-drug-information/abstract-text/10959939/pubmed" id="10959939" target="_blank">10959939</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7767184">
<a name="7767184"></a>Doona M and Walsh JB, “Use of Chloramphenicol as Topical Eye Medication: Time to Cry Halt?” <i>BMJ</i>, 1995, 310(6989):1217-8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chloramphenicol-pediatric-drug-information/abstract-text/7767184/pubmed" id="7767184" target="_blank">7767184</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30845331">
<a name="30845331"></a>Dyson ZA, Klemm EJ, Palmer S, Dougan G. Antibiotic resistance and typhoid. <i>Clin Infect Dis.</i> 2019;68(suppl 2):S165-S170. doi:10.1093/cid/ciy1111<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chloramphenicol-pediatric-drug-information/abstract-text/30845331/pubmed" id="30845331" target="_blank">30845331</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-13021568">
<a name="13021568"></a>Ferguson JW, Macfarlane JP. Depression of bone marrow activity after the use of chloramphenicol, with recovery. <i>Glasgow Med J</i>. 1953;34(1):22-25.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chloramphenicol-pediatric-drug-information/abstract-text/13021568/pubmed" id="13021568" target="_blank">13021568</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6886919">
<a name="6886919"></a>Freundlich M, Cynamon H, Tamer A, et al, “Management of Chloramphenicol Intoxication in Infancy by Charcoal Hemoperfusion,” <i>J Pediatr</i>, 1983, 103(3):485-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chloramphenicol-pediatric-drug-information/abstract-text/6886919/pubmed" id="6886919" target="_blank">6886919</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-850816">
<a name="850816"></a>Haile CA. Chloramphenicol toxicity. <i>South Med J</i>. 1977;70(4):479-480. doi:10.1097/00007611-197704000-00034<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chloramphenicol-pediatric-drug-information/abstract-text/850816/pubmed" id="850816" target="_blank">850816</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9590397">
<a name="9590397"></a>Hammett-Stabler CA and Johns T. Laboratory guidelines for monitoring of antimicrobial drugs. National Academy of Clinical Biochemistry. <i>Clin Chem.</i> 1998;44(5):1129-1140.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chloramphenicol-pediatric-drug-information/abstract-text/9590397/pubmed" id="9590397" target="_blank">9590397</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Heinonen.1">
<a name="Heinonen.1"></a>Heinonen OP, Slone D, and Shapiro S. <i>Birth Defects and Drugs in Pregnancy</i>. Littleton, MA: Publishing Sciences Group; 1977.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14226042">
<a name="14226042"></a>Keith CG. Optic atrophy induced by chloramphenicol. <i>Br J Ophthalmol</i>. 1964;48(10):567-570. doi:10.1136/bjo.48.10.567<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chloramphenicol-pediatric-drug-information/abstract-text/14226042/pubmed" id="14226042" target="_blank">14226042</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10318297">
<a name="10318297"></a>Klaus JR, Knodel LC, Kavanagh RE. Administration guidelines for parenteral drug therapy. Part I: pediatric patients. <i>J Pharm Technol</i>. 1989;5(3):101-128.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chloramphenicol-pediatric-drug-information/abstract-text/10318297/pubmed" id="10318297" target="_blank">10318297</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Kliegman.1">
<a name="Kliegman.1"></a>Kliegman RM and St. Geme J, eds. <i>Nelson Textbook of Pediatrics</i>. 21st ed. Philadelphia, PA: Saunders Elsevier; 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14412753">
<a name="14412753"></a>Kunin CM, Glazko AJ, and Finland M, “Persistence of Antibiotics in Blood of Patients With Acute Renal Failure. II. Chloramphenicol and Its Metabolic Products in the Blood of Patients With Severe Renal Failure Disease or Hepatic Cirrhosis,” <i>J Clin Invest</i>, 1959, 38(9):1498-508.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chloramphenicol-pediatric-drug-information/abstract-text/14412753/pubmed" id="14412753" target="_blank">14412753</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10494741">
<a name="10494741"></a>Lee AY, Yoo SH. Chloramphenicol induced acute generalized exanthematous pustulosis proved by patch test and systemic provocation. <i>Acta Derm Venereol</i>. 1999;79(5):412-413. doi:10.1080/000155599750010571<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chloramphenicol-pediatric-drug-information/abstract-text/10494741/pubmed" id="10494741" target="_blank">10494741</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-5416851">
<a name="5416851"></a>Levine PH, Regelson W, Holland JF. Chloramphenicol-associated encephalopathy. <i>Clin Pharmacol Ther</i>. 1970;11(2):194-199. doi:10.1002/cpt1970112194<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chloramphenicol-pediatric-drug-information/abstract-text/5416851/pubmed" id="5416851" target="_blank">5416851</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Long.1">
<a name="Long.1"></a>Long S, Pickering L, eds. Bacterial meningitis: antimicrobial therapy. <i>Principles and practice of pediatric infectious diseases.</i> 4th ed. Elsevier Inc; 2012.</div>
</li>
<li>
<div class="reference">
                  Long SS, Prober CG, Fischer M, eds. Bacterial meningitis: antimicrobial therapy. <i>Principles and practice of pediatric infectious diseases.</i> 5th ed. Elsevier Inc; 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6743732">
<a name="6743732"></a>Matsuda S. Transfer of antibiotics into maternal milk. <i>Biol Res Pregnancy Perinatol</i>. 1984;5(2):57-60.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chloramphenicol-pediatric-drug-information/abstract-text/6743732/pubmed" id="6743732" target="_blank">6743732</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Messick.1">
<a name="Messick.1"></a>Messick CR and Pendland SL, “<i>In Vitro</i> Activity of Chloramphenicol Alone and in Combination With Vancomycin, Ampicillin, or RP 59500 (Quinupristin/Dalfopristin) Against Vancomycin-Resistant Enterococci,” <i>Diagn Microbiol Infect Dis</i>, 1997, 29(3):203-5.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32265601">
<a name="32265601"></a>Meyers RS, Thackray J, Matson KL, et al. <i>K</i>ey Potentially <i>I</i>nappropriate <i>D</i>rugs in Pediatrics: The KIDs List. <i>J Pediatr Pharmacol Ther</i>. 2020;25(3):175-191.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chloramphenicol-pediatric-drug-information/abstract-text/32265601/pubmed" id="32265601" target="_blank">32265601</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Moffa.1">
<a name="Moffa.1"></a>Moffa M and Brook I; Tetracyclines, Glycylcyclines, and Chloramphenicol. In: Bennett JE, Dolin R, and Blaser MJ, eds. <i>Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases</i>. 8th ed. Philadelphia, PA: Elsevier, 2015.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Montoro.1">
<a name="Montoro.1"></a>Montoro A, Cao A, Ordoqui E, et al, “Contact Sensitivity to Chloramphenicol,” <i>J Allergy Clin Immunol</i>, 1995, 95:291.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6416440">
<a name="6416440"></a>Mulhall A, de Louvois J, Hurley R. Chloramphenicol toxicity in neonates: its incidence and prevention. <i>Br Med J (Clin Res Ed)</i>. 1983;287(6403):1424-1427. doi:10.1136/bmj.287.6403.1424<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chloramphenicol-pediatric-drug-information/abstract-text/6416440/pubmed" id="6416440" target="_blank">6416440</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6130304">
<a name="6130304"></a>Mulhall A, de Louvois J, Hurley R. Efficacy of chloramphenicol in the treatment of neonatal and infantile meningitis: a study of 70 cases. <i>Lancet</i>. 1983;1(8319):284-287.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chloramphenicol-pediatric-drug-information/abstract-text/6130304/pubmed" id="6130304" target="_blank">6130304</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7273601">
<a name="7273601"></a>Nahata MC and Powell DA, “Bioavailability and Clearance of Chloramphenicol After Intravenous Chloramphenicol Succinate,” <i>Clin Pharmacol Ther</i>, 1981, 30(3):368-72.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chloramphenicol-pediatric-drug-information/abstract-text/7273601/pubmed" id="7273601" target="_blank">7273601</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34264565">
<a name="34264565"></a>Nelson CA, Meaney-Delman D, Fleck-Derderian S, Cooley KM, Yu PA, Mead PS; The Centers for Disease Control and Prevention. Antimicrobial treatment and prophylaxis of plague: recommendations for naturally acquired infections and bioterrorism response. <i>MMWR Recomm Rep.</i> 2021;70(3):1-27. doi:10.15585/mmwr.rr7003a1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chloramphenicol-pediatric-drug-information/abstract-text/34264565/pubmed" id="34264565" target="_blank">34264565</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6868331">
<a name="6868331"></a>Plomp TA, Thiery M, and Maes RA, "The Passage of Thiamphenicol and Chloramphenicol Into Human Milk After Single and Repeated Oral Administration," <i>Vet Hum Toxicol</i>, 1983, 25(3):167-72.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chloramphenicol-pediatric-drug-information/abstract-text/6868331/pubmed" id="6868331" target="_blank">6868331</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14378658">
<a name="14378658"></a>Poulton EM. Thrombocytopenic purpura during chloramphenicol therapy. <i>Br Med J</i>. 1955;2(4931):106. doi:10.1136/bmj.2.4931.106<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chloramphenicol-pediatric-drug-information/abstract-text/14378658/pubmed" id="14378658" target="_blank">14378658</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-040026">
<a name="040026"></a>Powell DA, Nahata MC. Chloramphenicol: new perspectives on an old drug. <i>Drug Intell Clin Pharm</i>. 1982;16(4):295-300.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chloramphenicol-pediatric-drug-information/abstract-text/040026/pubmed" id="040026" target="_blank">040026</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2179837">
<a name="2179837"></a>Prober CG, Stevenson DK, Benitz WE. The use of antibiotics in neonates weighing less than 1200 grams. <i>Pediatr Infect Dis J</i>. 1990; 9:111-121.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chloramphenicol-pediatric-drug-information/abstract-text/2179837/pubmed" id="2179837" target="_blank">2179837</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7143156">
<a name="7143156"></a>Rajchgot P, Prober CG, Soldin S, et al. Initiation of chloramphenicol therapy in the newborn infant. <i>J Pediatr</i>. 1982; 101:1018-1021.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chloramphenicol-pediatric-drug-information/abstract-text/7143156/pubmed" id="7143156" target="_blank">7143156</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6839629">
<a name="6839629"></a>Rajchgot P, Prober CG, Soldin SJ, et.al. Toward optimization of therapy in the neonate. <i>Clinical Pharmacology and Therapeutics</i>. 1983;33(5):551-555.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chloramphenicol-pediatric-drug-information/abstract-text/6839629/pubmed" id="6839629" target="_blank">6839629</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3380586">
<a name="3380586"></a>Ramilo O, Kinane BT, and McCracken GH Jr, “Chloramphenicol Neurotoxicity,” <i>Pediatr Infect Dis J</i>, 1988, 7(5):358-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chloramphenicol-pediatric-drug-information/abstract-text/3380586/pubmed" id="3380586" target="_blank">3380586</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6800194">
<a name="6800194"></a>Schmitt-Gräff A. Chloramphenicol-induced aplastic anemia terminating with acute nonlymphocytic leukemia. <i>Acta Haematol</i>. 1981;66(4):267-268. doi:10.1159/000207133<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chloramphenicol-pediatric-drug-information/abstract-text/6800194/pubmed" id="6800194" target="_blank">6800194</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1749296">
<a name="1749296"></a>Smilack JD, Wilson WR, and Cockerill FR 3d, “Tetracyclines, Chloramphenicol, Erythromycin, Clindamycin, and Metronidazole,” <i>Mayo Clin Proc</i>, 1991, 66(12):1270-80.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chloramphenicol-pediatric-drug-information/abstract-text/1749296/pubmed" id="1749296" target="_blank">1749296</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Stout.1">
<a name="Stout.1"></a>Stout J. Clinical manifestations, diagnosis, and treatment of plague (Yersinia pestis infection). Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 17, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-13218741">
<a name="13218741"></a>Todd RM. The treatment of hypoplastic anaemia after chloramphenicol. <i>Arch Dis Child</i>. 1954;29(148):575-577. doi:10.1136/adc.29.148.575<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chloramphenicol-pediatric-drug-information/abstract-text/13218741/pubmed" id="13218741" target="_blank">13218741</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15494903">
<a name="15494903"></a>Tunkel AR, Hartman BJ, Kaplan SL, et al. Practice guidelines for the management of bacterial meningitis. <i>Clin Infect Dis</i>. 2004;39(9):1267-1284.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chloramphenicol-pediatric-drug-information/abstract-text/15494903/pubmed" id="15494903" target="_blank">15494903</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2183667">
<a name="2183667"></a>Tunkel AR, Wispelwey B, and Scheld M, “Bacterial Meningitis: Recent Advances in Pathophysiology and Treatment,” <i>Ann Intern Med</i>, 1990, 112(8):610-23.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chloramphenicol-pediatric-drug-information/abstract-text/2183667/pubmed" id="2183667" target="_blank">2183667</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-OSHA.1">
<a name="OSHA.1"></a>US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href="https://www.cdc.gov/niosh/docs/2016-161/default.html" target="_blank">https://www.cdc.gov/niosh/docs/2016-161/default.html</a>. Updated September 2016. Accessed October 5, 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3359738">
<a name="3359738"></a>Vozeh S, Schmidlin O, and Taeschner W, “Pharmacokinetic Drug Data,” <i>Clin Pharmacokinet</i>, 1988, 15(4):254-82.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chloramphenicol-pediatric-drug-information/abstract-text/3359738/pubmed" id="3359738" target="_blank">3359738</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-13843700">
<a name="13843700"></a>Weiss CF, Glazko AJ, Weston JK. Chloramphenicol in the newborn infant. <i>New Engl J Med</i>. 1960;262(16):787-794.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chloramphenicol-pediatric-drug-information/abstract-text/13843700/pubmed" id="13843700" target="_blank">13843700</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WHO.1">
<a name="WHO.1"></a>World Health Organization (WHO). Breastfeeding and maternal medication, recommendations for drugs in the Eleventh WHO Model List of Essential Drugs. 2002. Available at https://apps.who.int/iris/handle/10665/62435
                  </div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2254575">
<a name="2254575"></a>Yoshikawa TT, “Antimicrobial Therapy for the Elderly Patient,” <i>J Am Geriatr Soc</i>, 1990, 38(12):1353-72.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chloramphenicol-pediatric-drug-information/abstract-text/2254575/pubmed" id="2254575" target="_blank">2254575</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3289495">
<a name="3289495"></a>Yunis AA, “Chloramphenicol: Relation of Structure to Activity and Toxicity,” <i>Annu Rev Pharmacol Toxicol</i>, 1988, 28:83-100.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chloramphenicol-pediatric-drug-information/abstract-text/3289495/pubmed" id="3289495" target="_blank">3289495</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 13145 Version 375.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
